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Abstract: This review critically analyzes how machine learning is being utilized to 
support clinical decision-making in the management of potentially resectable 
pancreatic cancer. Following PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) guidelines, electronic searches of MEDLINE, Embase, 
PubMed and Cochrane Database were undertaken. Studies were assessed using the 
Checklist for critical Appraisal and data extraction for systematic Reviews of 
prediction Modeling Studies (CHARMS) checklist. In total 89,959 citations were 
retrieved. Six studies met the inclusion criteria. Three studies were Markov decision-
analysis models comparing neoadjuvant therapy versus upfront surgery. Three studies 
predicted survival time using Bayesian modeling (n = 1), Artificial Neural Network (n 
= 1), and one study explored machine learning algorithms including: Bayesian 
Network, decision trees, k-nearest neighbor, and Artificial Neural Networks. The 
main methodological issues identified were: limited data sources which limits 
generalizability and potentiates bias, lack of external validation, and the need for 
transparency in methods of internal validation, consecutive sampling, and selection of 
candidate predictors.  The future direction of research relies on expanding our view of 
the multidisciplinary team to include professionals from computing and data science 
with algorithms developed in conjunction with clinicians and viewed as aids, not 
replacement, to traditional clinical decision-making.  
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Introduction  
The management of pancreatic cancer is particularly challenging.1,2 Surgical resection 
is the only potentially curative treatment yet despite advances in surgical technique 
and adjuvant therapies 10-year survival remains less than 1%.3 Surgical risks remain 
high with any potential benefit often nullified by early disease reoccurrence.4,5 
 
Several factors have aligned making decision-making in the management of 
pancreatic cancer more complex. The ageing population and obesity epidemic means 
patients are amassing a greater amount of clinical data to consider when making 
clinical decisions.6 Treatment options are expanding with the emergence of 
neoadjuvant approach as an alternative to upfront surgery. While some are optimistic 
about the role of neoadjuvant therapy, others feel the current body of evidence is at 
best ambiguous with its role in the management of resectable pancreatic cancer being 
particularly controversial.7-12 This is compounded by the current lack of randomized 
controlled trials comparing both upfront surgery and neoadjuvant treatment 
pathways.12 Furthermore through the emergence of precision medicine databases will 
expand to reflect our understanding of disease at genomic level, creating a further 
‘data explosion’.13 Patients therefore represent a big data challenge not only in 
amount of data amassed, but in being extremely complex data systems with 
multidimensional problems and interacting parameters with the rules governing 
behaviours within layers of these systems often unclear or simply unknown.14 
 
Personalized predictive modeling has gained precedence as a means of supporting 
clinical decision-making.15 However, existing predictive models, mainly based on 
non-liner regression techniques are limited in scope and volume regarding prognosis 
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as an isolated event at a pre-determined time.15,16 Machine learning methods make 
predictions within complex systems against a background of competing risks and 
events.14 Machine learning achieves this in one of three ways. Firstly supervised 
learning, where the computer utilizes partial labeling of data.17,18 Alternatively 
unsupervised learning allows the computer to make predictions or explain data by 
utilizing structures detected within the data itself.17,18 Thirdly reinforcement learning 
whereby, similar to operant conditioning,19 the computer learns from its mistakes and 
successes to achieve a task.17,20 Commonly employed methods of machine learning 
include, but are not limited to: Bayesian networks (BN), artificial neural networks 
(ANN) and Fuzzy-logic (FL) modeling.14 Table 1 outlines the definition, strengths 
and limitations of these most commonly employed methods of machine learning.      
 
In isolation the factors outlined as contributing to the complexity of decision-making 
may not be unique to pancreatic cancer. However, in the context of being one of the 
most challenging malignancies,1,2 with comparatively lower resection rates compared 
to other gastrointestinal malignancies,1-3 pancreatic cancer is the ideal vehicle to 
critically examine how successful machine learning is in dealing with complexity and 
uncertainty to support clinical decision-making.  
 
The aim of this review is to use the Checklist for critical Appraisal and data extraction 
for systematic Reviews of prediction Modeling Studies (CHARMS) checklist21 to 
critically analyze the use of machine learning for decision-analysis, prognostic and 
predictive purposes to support clinical decision-making in the management of 
potentially resectable pancreatic cancer.  
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METHODS 
The protocol for this review was published in the PROSPERO online database of 
systematic reviews (CRD42018108926). Electronic searches of MEDLINE, Embase, 
PubMed and Cochrane Database were undertaken with the entire databases included 
up to and including 14th September 2018, with no further date restrictions or limits 
applied. Full search strategies are detailed in Supplementary Digital Content 1. This 
review followed the PRISMA checklist.22 
Study Selection  
Manual screening was carried out after removal of duplicates, based on the title and 
abstract of articles identified in the database searches. Articles of probable or possible 
relevance were reviewed in full. This was decided based on the inclusion criteria of 
machine learning methods applied to pancreatic cancer management decision support, 
published in full-text in English language. This included predictive and prognostic 
modeling and decision-analysis studies. Application of machine learning to diagnosis, 
interpretation of diagnostic imagery, and risk of developing pancreatic cancer were 
excluded. The focus was on application of machine learning to support clinical 
decision-making in the management of pancreatic cancer, following diagnosis, 
including prediction of survival, quality adjusted survival, and complications of 
treatments. The reason for this focus is that it is anticipated that personalized 
predictive medicine will be able to forecast individualized outcomes across competing 
treatment strategies to facilitate clinical decision-making. Given the afore mentioned 
ambiguities and controversies regarding the best management pathways for 
potentially resectable pancreatic cancer,7-12 this is the ideal vehicle through which to 
assess the contribution of machine learning in supporting clinical decision-making 
under uncertainty across the ever evolving patient journey. Reference lists and 
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citations of all included papers were manually searched to identify any additional 
articles. This process was repeated until no new articles were identified. 
Data Extraction, Quality Assessment, and Data Analysis  
Search design and data extraction were performed by the lead reviewer and with 
second author performing independent quality assurance. Discrepancies were resolved 
by inter-reviewer discussion. For predictive models data was extracted according to 
the CHARMS checklist, which also includes assessment of risk of bias.21 This 
checklist is designed for appraisal of all primary prediction modeling studies 
including ANN and vector machine learning.21  
RESULTS 
Search Results 
Abstracts of 89,959 citations were retrieved. Six studies met the inclusion criteria of 
machine learning methods applied to predictive modeling and decision-analysis 
related to pancreatic cancer management (Fig. 1).  
Three studies were Markov decision-analysis models comparing two competing 
treatment options: neoadjuvant therapy versus upfront surgery.23-25 Three studies 
focused on predicting survival time.26-28 One of these studies also predicted lymph 
node ratio.26 One of these studies additionally explored prediction of Eastern 
Cooperative Oncology Group (ECOG) quality-of-life scores, surgical outcomes and 
tumour characteristics.27 One study performed direct comparison between predictive 
accuracy of machine learning techniques and linear and logistic regression.27  
Three studies used Marko decision tree models,23-25 1 study used Bayesian 
modeling,26 1 study used ANN,28 and 1 study explored machine learning algorithms 
including: BN, decision trees, k-nearest neighbor, and ANN (Table 2).27  
Decision-analysis Models 
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Three studies attempted to employ Markov decision analysis to compare upfront 
surgery and neoadjuvant approach.23-25 Sharma et al24 used data drawn from 21 
prospective phase II and III trials. De Gus et al23 also included data from retrospective 
studies compiled from a literature search from a single search engine. Both these 
studies, although reportedly analyzing strategies for resectable pancreatic cancer used 
studies that included borderline resectable and locally advanced pancreatic cancer in 
an intention-to-treat analysis.23,24 All 3 studies used an intention-to-treat approach to 
analysis and, although they reported a slight benefit from neoadjuvant approach, 
neither strategy was conclusively superior.23-25 All three existing studies were solely 
based on synthesized evidence from published trials therefore share the limitations of 
the existing body of evidence mainly: heterogeneity and small underpowered sample 
size.7,8  
Prediction Models 
A cohort design, commonly recommended for prognostic model development,29 was 
used for all 3 predictive models.26-28 Two studies used retrospective single center 
databases (ANN, n = 21928; comparison study, n = 9127), which can limit 
generalizability, and 1 study used cancer data registry (BN, n = 6400).26 Prospective 
cohort designed is recommended as it enables optimal measurement of predictors and 
outcome.30 Retrospective cohorts are thought to yield poorer quality data but do 
enable longer follow-up time.29     
Participant recruitment with inclusion criteria and description of cohort characteristics 
were well reported, as were study dates in all 3 studies.26-28 Length of follow-up time 
was clear in 2 studies.26,28 Consecutive sampling was reported in 1 study28 but 
whether all consecutive participants were included, or number of participants who 
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refused to participate, could not be evaluated in any of the 3 studies.26-28 Non-
consecutive sampling can introduce a risk of bias.31-33  
In all 3 studies outcomes were clearly defined with the same outcome definition and 
method of measurement applied to all patients.26-28 The interactive Bayesian model 
predicted 6 month, 1-, 3- and 5-year survival post resection and lymph node ratio.26 
The ANN predicted 7-month mortality after resection.28 Hayward et al focused on 
data mining techniques but treated survival outcome as a time-dependent-event for 
resected and un-resected patients, with ECOG measured at 6 months post-resection.27 
Number of candidate variables ranged from 7 to 19. The definition, method and 
timing of measurement of candidate predictors were clear in all 3 studies.26-28 How 
candidate predictors were selected were not made clear in 2 studies26,28 which may be 
illustrative of the non-transparent ‘black-box’ analysis sometimes employed by forms 
of artificial intelligence (AI). One study extensively explored algorithms for data 
mining and categorization of the datasets.27 The other two studies used backward 
elimination methods.26,28 The ANN used single hidden layer back propagation to train 
the model,28 and the Bayesian model employed backward step down selection 
process.26 All 3 studies used complete case analysis.26-28 This approach results in loss 
of statistical power and can introduce bias as missing data rarely occurs randomly and 
often pertains to participant or disease characteristics.30  
None of the studies underwent external validation. The interactive Bayesian model26 
and ANN28 employed random split technique between training and validation 
datasets. This points to a potential key weakness in the application of machine 
learning techniques as random split technique can result in over and under fitting of 
the model, particularly as details of cross validation were not given.34 Techniques of 
data splitting are poorly described and can result in a high degree of variance of 
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model performance.34 More sophisticated techniques of data splitting that exploit the 
structure of the data exist and provide more confident results, but at higher 
computational cost.34 Only the interactive Bayesian model reported calibration with 
goodness-of-fit statistic (P = 0.300 for prediction of lymph-node-ratio; P = 0.4847 for 
survival prediction).26 The ANN reported discrimination as area under curve (AUC) 
of the receiver operated curve (ROC) (AUC, 0.6576; sensitivity, 91.30%; specificity, 
38.27%).28 The interactive Bayesian model reported discrimination as c-statistic 
(0.65; 95% confidence interval [CI], 0.63–0.66).26 Although commonly used, the c-
statistic can be influenced by predictor value distribution and be insensitive to 
inclusion of additional predictors.21 The study by Hayward et al. compared machine 
learning to log regression and found that for survival prediction Bayesian modeling 
out performed log regression (accuracy 0.60 versus 0.42).27 Furthermore in predicting 
outcome for ECOG at 6 months post-resection log regression performance improved 
from r-squared value, 0.26 to 0.32 when modified with machine learning algorithm 
‘linear regression with bagging’.27 
DISCUSSION 
Principal Findings 
Our review found 6 studies applying machine learning techniques to support clinical 
decision-making in the management of pancreatic cancer. Three studies used Markov 
decision tree models to perform decision analysis.23-25 Three studies used machine 
learning methods for predictive modeling: 1 study used Bayesian modeling,26 1 study 
used ANN,28 and 1 study explored machine learning algorithms including: BN, 
decision trees, k-nearest neighbor, and ANN.27 The main issues identified with 
decision-analysis studies were reliance on data from a single database search and the 
quality of the existing studies pertaining to treatment of potentially resectable 
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pancreatic cancer being mainly small and underpowered with a high degree of 
heterogeneity.7,8 The issues identified with the predictive models were overreliance on 
single institution retrospective database, which could affect generalizability. There 
was also a lack of clarity as to whether consecutive sampling was employed and how 
candidate predictors were selected. A major issue identified was lack of external 
validation across all 3 predictive models. Although 2 studies used random-split 
technique, details of cross-validation were not provided which potentiates issues of 
over or under fitting. Only one study reported calibration of their model.  
Implications for Research and Practice 
Machine learning, although in its infancy, holds great potential in its application to 
decision-making under complexity.14,35 However the application of machine learning 
to predictive modeling pertaining to the management of pancreatic cancer is currently 
limited in number therefore no conclusion can yet be drawn as to superiority of either 
machine learning or traditional modeling approaches. Only one study directly 
compared machine-learning methods with traditional approach to modeling.27 
Accuracy of machine learning predictions, particularly Bayesian modeling, were 
found to be superior and predictions form log regression approach were improved 
when combined with machine learning techniques.27 However, it is important to note 
that of existing predictive studies using machine learning limitations in 
methodological approach were identified using the CHARMS checklist.21 These 
issues are similar to issues highlighted in traditional approaches to predictive 
modeling and include: use of single centre database limiting generalizability, sample 
size, lack of blinding, transparency in candidate predictor selection, and lack of 
external validation.21, 29-32  
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Whilst much optimism surrounds the growing use for AI in healthcare delivery, 
machine learning also carries limitations that must be addressed in future research. 
Machine learning usually requires large amounts of data,36 which in the case of 
management of potentially resectable pancreatic cancer can be difficult to obtain as 
the majority of patients present with advanced, unresectable disease.1-3 Whilst the 
creation of national shared databases may be one solution to increase the volume of 
data, this is not without issue including dimensionality, missing data and control of 
bias37,38 with minority groups often under represented in such databases.38 
Furthermore simply increasing volume of data is not the solution as machine learning 
is not yet at a stage where it can distinguish correlation and causation.36 Future 
research should focus on better integration of machine learning with expert 
knowledge to overcome this challenge.36 This review found little evidence of machine 
learning being actively integrated into clinical practice. Whilst this is mainly due to 
such techniques being in their infancy, it must also be acknowledged that some 
machine learning techniques are not yet sufficiently transparent which breeds distrust 
and resistance to their clinical application.36 Machine learning requires high levels of 
technical skill and can be difficult to engineer with experts from medicine, computing 
and data sciences often speaking in different technical language and coming to 
problems from different perspectives which can inhibit shared understanding and 
limit achievement of its full potential.36 The solution therefore lies with clinicians 
expanding their view of the multidisciplinary team to include professionals from 
computing and data science backgrounds with algorithms developed in conjunction 
with clinicians and viewed as aids, not replacement, to traditional clinical decision-
making.6     
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Despite these challenges the study by Hayward et al27 does however corroborate other 
studies where application of machine-learning methods to: breast, prostate and 
bladder cancers have demonstrated superiority in terms of accuracy of predictions 
over traditional log regression.39-42 Artificial Neural Networks have also been found 
to perform as well as or better than traditional log regression models and also improve 
the diagnosis and management of pancreatitis and diagnosis pancreatic cancer.35 
Machine learning methods have also been shown to out perform log regression in: 
providing individualized prediction of the need for neonatal resuscitation,43 predicting 
early mortality risk in coronary artery bypass graft surgery44 and predicting severely 
depressed left ventricular ejection fraction following admission to intensive care 
unit.45  
Strengths and Limitations 
Although limited to studies available in English language, this review is the first of its 
kind and goes beyond the hype surrounding use of machine learning and AI in 
supporting clinical decision-making to ascertain what the current reality of its 
application to clinical practice in management of potentially resectable pancreatic 
cancer actually is. Furthermore it highlights limitations that should be addressed in 
future research. The current number of existing studies is limited therefore 
conclusions about superiority of machine learning over traditional predictive 
modeling techniques are limited.  
CONCLUSION 
To conclude clinical decision-making is going to become increasingly complex as our 
understanding of disease and treatment response at genomic level grows, resulting in 
a further ‘data explosion’.6,13,14 Utilizing this expanse of data to facilitate decision-
making in a meaningful way for individual patients is beyond the capabilities of the 
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human mind working in isolation.6,14,35 It is in this context that machine learning 
holds the greatest potential by being able to handle large amounts of data and 
integrate large, complex and varied databases.35 However machine learning also 
carries limitations and, whilst initial studies are promising, its application has yet to 
be widely tested.36 The future direction of research therefore relies on expanding our 
view of the multidisciplinary team to include professionals from computing and data 
science backgrounds with algorithms developed in conjunction with clinicians and 
viewed as aids, not replacement, to traditional clinical decision-making.6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
REFERENCES  
1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2015. CA Cancer J Clin. 
2015;6:5-29. 
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and 
mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 
2013;49:1374-1403. 
3. Pancreatic Cancer UK. Pancreatic Cancer UK policy briefing: every life 
matters: the real cost of pancreatic cancer diagnosis via emergency admission. 
Available at https://www.pancreaticcancer.org.uk/media/86662/every-
im_policybriefing-final.pdf. Accessed September 2, 2017. 
4. Winter JM, Brennan MF, Tang LH, et al. Survival after Resection of 
Pancreatic Adenocarcinoma: Results from a Single Institution over Three 
Decades. Ann Surg Oncol. 2012;19:169.  
5. Lewis RS, Vollmer CM. Risk scores and prognostic models in surgery: 
pancreas resection as a paradigm. Curr Probl Surg. 2012;49:731-795. 
6. Obermeyer ZMD, Lee TH. Lost in Thought — The Limits of the Human Mind 
and the Future of Medicine. N Engl J Med. 2017;377:1209-1211. 
7. Tempero MA, Malafa MP, Behrman SW. Pancreatic adenocarcinoma, version 
2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 
2014;12:1083–1093. 
8. Asare EA, Evans DB, Erickson BA, et al. Neoadjuvant treatment sequencing 
adds value to the care of patients with operable pancreatic cancer. J Surg 
Oncol. 2016;114:291-295. 
 15 
9. Lee J, Ahn S, Paik K, et al. Clinical impact of neoadjuvant treatment in 
resectable pancreatic cancer: a systematic review and meta-analysis protocol. 
BMJ. 2016;6:1-9. 
10. Xu CP, Xue XJ, LaingN, et al. Effect of chemoradiotherapy and neoadjuvant 
chemoradiotherapy in resectable pancreatic cancer: a systematic review and 
meta-analysis. J Cancer Res Clin Oncol. 2014;140:549-559. 
11. Andriulli A, Festa V, Botteri E, et al.  Neoadjuvant/preoperative gemcitabine 
for patients with localized pancreatic cancer: a meta-analysis of prospective 
studies. Ann Surg Oncol. 2012;19:1644-1662. 
12. Versteijjne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing 
upfront surgery with neoadjuvant treatment in patients with resectable or 
borderline resectable pancreatic cancer. BJS. 2018;105: 946-958.  
13. Tonelli MR, Shirts BH. Knowledge for Precision Medicine Mechanistic 
Reasoning and Methodological Pluralism. JAMA. 2017;318:1649–1650. 
14. Abbod MF, Hamdy FC, Linkens DA, et al. Predictive modeling in cancer: 
where systems biology meets the stock market. Expert Review of Anticancer 
Therapy. 2014;9:867-870. 
15. Velikova M, Scheltinga JT, Lucas PJF, et al. Exploiting causal functional 
relationships in Bayesian network modeling for personalized healthcare.  Int 
Journal of Approximate Reasoning. 2014;55:59-73.   
16. Verduijn M, Peek N, Rosseel PMJ, et al. Prognostic Bayesian networks I: 
rationale, learning procedure, and clinical use. Journal of Biomedical 
Informatics. 2017; 609-618. 
17. Hashimoto DA, Rosman G, Rus D, et al. Artificial Intelligence in Surgery: 
promises and perils. Annals of Surgery. 2018;286:70-76. 
 16 
18. Deo RC. Machine learning in medicine. Circulation. 2015;132:1920-1930. 
19. Skinner BF. The behaviour of organisms: An experimental analysis. New 
York, NY: Appleton-Century-Crofts; 1938. 
20. Sutton RS, Barto AG. Reinforcement learning: An Introduction. Vol. 1. 
Cambridge: MIT Press; 1998.  
21. Moons KGM, de Groot JAH, Bouwmeester W, et al. Critical Appraisal and 
Data Extraction for Systematic Reviews of Prediction Modelling Studies: The 
CHARMS Checklist. PLoS Med. 2014;11:e1001744. 
22. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic 
reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3:123-
130. 
23. deGus SW, Evans DB, Bliss LA, et al. Neoadjuvant therapy versus upfront 
surgical strategies in resectable pancreatic cancer: a Markov decision analysis. 
Eur J Surg. 2016;42:1552-1560.  
24. Sharma G, Whang EE, Ruan DT, et al. Efficacy of neoadjuvant versus 
adjuvant versus adjuvant therapy for resectable pancreatic adenocarcinoma: a 
decision analysis. Ann Surg Oncol. 2015;22:1229-1237. 
25. VanHouten JP, White RR, Jackson GP. A Decision Model of Therapy for 
Potentially Resectable Pancreatic Cancer. J Surg Res. 2012;174:222-230. 
26. Smith BJ, Mezhir JJ. An interactive Bayesian model for prediction of lymph 
node ratio and survival in pancreatic cancer patients. J Am Med Inform Assoc. 
2014;21:203-211. 
27.  Hayward J, Alvarez SA, Ruiz C, et al. Machine learning of clinical 
performance in a pancreatic cancer database. Artificial Intelligence. 
2010;49:187-195.   
 17 
28. Walczak S, Velanovich V. An evaluation of Artificial Neural Networks in 
predicting pancreatic cancer survival. J Gastrointest Surg. 2017;21:1606-
1612.  
29. Moons KG, Royston P, Vergouwe Y, et al. Prognosis and prognostic research: 
what, why, and how? BMJ. 2009;338:375.  
30. Bouwmeester W, Zuithoff NPA, Mallett S, et al. Reporting and Methods in 
Clinical Prediction Research: A Systematic Review. PLoS Med. 
2012;9:e1001221.  
31. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ. 
2001;323:224–228.  
32. Altman DG, Vergouwe Y, Royston P, et al. Prognosis and prognostic 
research: validating a prognostic model. BMJ. 2009;338:1432–1435.  
33. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for 
reporting randomized trials: explanation and elaboration. Ann Intern Med. 
2001:134;663–694. 
34. Reitermanov ́a Z. Data Splitting. WDS'10 Proceedings of Contributed Papers, 
Part I. 2010; 31–36. 
35. Bartosch‐ Härlid A, Andersson B, Aho U, et al. Artificial neural networks in 
pancreatic disease. Br J Surg. 2008;95:817-826.  
36. Marcus G. Deep learning: a critical appraisal. arXiv. 2018; 1-27. 
37. Lee CH, Yoon HJ. Medical big data: promise and challenges. Kidney 
Research and Clinical Practice. 2017;36:3–11.  
38. Zhang X, Perez-Stable EJ, Bourne P, et al. Big Data Science: Opportunities 
and Challenges to Address Minority Health and Health Disparities in the 21st 
Century. Ethnicity & Disease. 2017; 27:95–106. 
 18 
39. Seker, H. A fuzzy logic based-method for prognostic decision making in 
breast and prostate cancers. IEE Transactions on Information Technology in 
Biomedicne. 2003;2:114-122. 
40. Catto JW, Linkens DA, Abbod MF, et al. Artificial intelligence in predicting 
bladder cancer outcome: a comparison of neuro-fuzzy modelling and artificial 
neural networks. Clin Cancer Res. 2003;9:4172-4177. 
41. Abbod, M.F. Linkens DA, Catto JWF, et al. Comparative study of intelligent 
models for the prediction of bladder cancer progression. Oncology. 
2006;15:1019-1022. 
42. Catto JW, Abbod MF, Linkens DA, et al. Neurofuzzy modelling to determine 
recurrence risk following radical cystectomy for nonmetastatic urothelial 
carcinoma of the bladder. Clin Cancer Res. 2009;15:3150-3155. 
43. Reis MA, Ortega NR, Silveira PS. Fuzzy expert system in the prediction of 
neonatal resuscitation. Braz J Med Biol Res. 2004;37:755-765. 
44. Ghavidel AA, Javadikasgari H, Maleki M, et al. Two new mathematical 
models for prediction of early mortality risk in coronary artery bypass graft 
surgery. J Thorac Cardiovasc Surg. 2014;148:1291-1298. 
45. Pereira RDMA, Salgado CM, Dejam A, et al. Fuzzy modelling to predict 
severely depressed left ventricular ejection fraction following admission to the 
intensive care unit using clinical physiology. The Scientific World Journal. 
2015;1-9.  
46. Lucas PJF, Gaag LC, Abu-Hanna A. Bayesian networks in biomedicine and 
health-care. Artificial Intelligence in Medicine. 2004;201-214. 
47. Schoot R, Kaplan D, Denissen J, et al. A gentle introduction to bayesian 
analysis: applications to developmental research. Child Dev. 2013;85:842-860. 
 19 
48. Hampson LV, Whitehead J, Eleftheriou D, et al. Bayesian methods for the 
design and interpretation of clinical trials in very rare diseases. Stat Med. 
2014;33:4186-4201. 
49. Johnson SR, Tomlinson GA, Hawker GA, et al. Methods to elicit beliefs for 
Bayesian prior: a systematic review. J Clin Epidemiol. 2010;63:355-369 
50. Gursel G. Healthcare, uncertainty, and fuzzy logic. Dig Med. 2016;2:101-112 
51. Barro S, Marín R, editors. Fuzzy Logic in Medicine. Vol. 83. Berlin 
Heidelberg, Germany: Springer; 2002.  
52. Dweiri FT, Kablan MM. Using fuzzy decision making for the evaluation of 
the project management internal efficiency. Decis Support Syst. 2006;42:712-
726. 
53. Grossi E. Medical concepts related to individual risk are better explained with 
“plausibility” rather than “probability”. BMC Cardiovasc Disord. 2015;5:31 
54. McNeill FM, Thro E. Fuzzy Logic: A Practical Approach. Cambridge, MA: 
Academic Press Professional; 1994 
55. Bouchon-Meunier B, Zadeh LA. Fuzzy logic and its applications. Paris, 
France: Addison-Wesley; 1995. 
56. Roychowdhury A, Pratihar DK, Bose N, et al. Diagnosis of the diseases-using 
a GA-fuzzy approach. Inf Sci. 2004;162:105-120. 
57. Pratihar DK, Deb K, Ghosh A. A genetic-fuzzy approach for mobile robot 
navigation among moving obstacles. Int J Approx Reason.1999;20:145-172.  
 
  
 20 
FIGURE LEGENDS 
FIGURE 1. PRISMA Flow Chart 
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Tables:  
TABLE 1. Summary of Common Methods of Machine Learning 
Method Application Strengths Limitations 
Bayesian Network (BN) Decision support 
Risk Assessment 
Prediction14-16,46 
Allows for incorporation of 
individual patient data, 
disease progression and 
impact of different 
treatment options on the 
predicted outcome.15,16 
  
Facilitates prognosis 
updating and scenario 
testing.16  
 
Provides information on 
process and outcome 
variables therefore predict 
outcomes pertaining to 
quality and not just 
amount of survival 
time.16,46 
 
Uses probabilistic 
inference when data is 
limited and can still make 
predictions based on 
global averages of the 
patient population.16,46 
Accurate use of data in 
elicitation of priors is an 
area of ongoing 
investigation and debate.46-
49 
 
An over reliance on 
machine-learned network 
structures, could mean 
fundamental causal 
relationships well 
established in medical 
knowledge are lost hence 
limiting the applicability.46-
49 
  
Can only model linear 
dependencies.14 
 
Artificial Neural Network 
(ANN) 
Modeling  
Prediction 
Image interpretation 
Classification14 
Models non-linearity and 
complex relationships.14,35 
Handles high-dimension  
problems.14,35 
Can generalize.35 
Does not impose any 
restrictions on the input 
variables.14,35  
Heavy data requirements 
with long training times 
requiring many design 
decisions.14,35 
May not generalize well to 
other data sets.14,35 
Lacks transparency.14,35 
 
 
Fuzzy Logic (FL) Modeling  
Prediction 
Classification14 
Models non-linearity.14  
 
Handles uncertainty and 
complexity.49-52  
 
Enables prediction to move 
from probability to 
plausibility.53  
 
Transition to a contiguous 
value is gradual rather 
than abrupt reflecting 
human decision-making 
processes.50,54,55  
 
Can assess more observed 
variables yet fewer values 
are required.54,55  
Transparent.14 
 
Extensive expert 
knowledge of the system to 
be modeled is required.56  
 
Requires more fine-tuning 
and simulation prior to 
being operational.57  
 
Cannot model high-
dimension problems.14 
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TABLE 2.Summary of Included Studies  
Study 
Participant 
Population Method Outcome Measure Main Limitations 
deGus et al, 201623 Synthesized data from 
phase II trials and 
cohort studies 
Markov decision-
analysis 
Survival in months 
and quality adjusted 
life months for 
upfront surgery versus 
neoadjuvant therapy 
Use of single 
electronic database of 
journals 
Synthesized small 
underpowered studies 
with high level if 
heterogeneity  
Relied heavily on 
retrospective cohort 
studies 
Sharma et al, 201524 Synthesized data from 
phase II trials 
Markov decision-
analysis 
Survival in months 
and quality adjusted 
life months for 
upfront surgery versus 
neoadjuvant therapy 
Use of single 
electronic database of 
journals 
Synthesized small 
underpowered studies 
with high level if 
heterogeneity 
VanHouten et al, 
201225 
Synthesized data from 
phase II trials and 
cohort studies 
Markov decision-
analysis 
Survival in months 
and quality adjusted 
life months for 
upfront surgery versus 
neoadjuvant therapy 
Use of single 
electronic database of 
journals 
Synthesized small 
underpowered studies 
with high level if 
heterogeneity 
Included borderline 
resectable cases in 
neoadjuvant cohort 
Relied heavily on 
retrospective cohort 
studies 
Smith & Mezhir, 
201426 
Cancer Registry (n = 
6400) 
Interactive Bayesian 
Model 
Survival at 6 months, 
1,3 and 5-year 
survival 
Follow-up time 
unclear 
Unclear if consecutive 
sampling used 
Selection method of 
candidate predictors 
not clear 
Complete base 
analysis used 
No external validation 
Walczak 
&Velanovich, 201728 
Retrospective single 
institution database (n 
= 219) 
Artificial Neural 
Network 
Death at 7 months 
post resection 
Consecutive sampling 
used but unclear all 
consecutive 
participants included 
Selection method of 
candidate predictors 
not clear 
Complete base 
analysis used 
No external validation 
No calibration 
Hayward et al, 201027  Retrospective single 
institution database (n 
= 91) 
Machine learning 
algorithms including: 
Bayesian Network, 
decision trees, k-
nearest neighbor, and 
ANN 
Survival as time 
dependent event, 
Eastern Cooperative 
Oncology Group 
(ECOG) quality-of-
life scores measured 
at 6 months 
Unclear if consecutive 
sampling used 
Complete base 
analysis used 
No external validation 
No calibration 
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Records identified through database 
searching 
(n = 89,959) 
PubMed/Medlin: n = 708 
Cochrane Library: n = 68 
Embase: n = 56,523 
GoogleScholar: 32,660 
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Records screened after duplicates removed 
(n = 23,097) 
Records screened 
(n = 259) 
Records excluded after review 
of title and abstract as not 
relevant to research question 
(n = 22,838) 
Full-text articles assessed 
for eligibility 
(n = 6) 
Studies included in 
qualitative synthesis 
(n = 6) 
Studies included in 
quantitative synthesis (n = 
6; meta-analysis not 
conducted) 
Duplicates removed 
(n = 66,862) 
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